Kigninlman Horo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kigninlman Horo has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
E. Aka-Danguy
Service de pneumologie, CHU de Cocody, BP 582, Abidjan cedex 03, Côte d'Ivoire
11 shared publicationsN. Koffi
Service de pneumologie, CHU de Cocody, BP 582, Abidjan cedex 03, Côte d'Ivoire
6 shared publicationsA.B. Kouassi
Service de pneumologie du CHU de Cocody, Cocody, Côte d'Ivoire
5 shared publicationsB.A. Kouassi
Service de pneumologie, CHU de Cocody, BP 582, Abidjan cedex 03, Côte d'Ivoire
5 shared publicationsA. Koné
Service de pneumologie, CHU de Cocody, BP 582, Abidjan cedex 03, Côte d'Ivoire
4 shared publicationsA. N’gOm
Service de pneumologie, centre hospitalier universitaire de Cocody, université Felix-Houphouet-Boigny, Abidjan, Côte d'Ivoire
4 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2269
Improving Management of Viral Febrile Illness and Reducing the Need for Empiric Antibiotics Using VIDAS® Immunoassay for Dengue and Chikungunya: A West African Multicentric Study
Background: Dengue and chikungunya are endemic in West Africa, posing significant public health issues. The aim of this study was to evaluate the impact of differential and systematic diagnosis of dengue and chikungunya on patient management and on antibiotic use in Burkina Faso and Ivory Coast. Methods: A multicenter prospective cohort study was conducted in both countries involving patients with suspected dengue and/or chikungunya viremia. VIDAS® diagnostic tests (bioMérieux SA, Marcy-l’Étoile, France) were provided to the intervention sites, while the control sites initially followed standard of care before testing at the end of the study. The primary outcome was defined as antibiotic prescription or non-initiation/discontinuation, and the secondary endpoints included hospital resource use, patient satisfaction, and health-related quality of life (HRQoL), analyzed through Chi-square and logistic regression using SAS software v9.4. Results: Out of 775 enrolled patients, 767 had corresponding VIDAS® Dengue and VIDAS® Chikungunya results, with 570 having recorded antibiotic therapy (initiated, non-initiated or discontinued). Both Burkina Faso and Ivory Coast observed an increase in antibiotic discontinuation (or non-initiation) rates at the intervention sites compared to control sites: increased from 60% to 78% in Burkina Faso and from 36% to 83% in Ivory Coast. Hospitalization rates within seven days following inclusion were also lower in intervention sites than in the control sites: Burkina Faso 41% as compared with 97% and Ivory Coast 24% as compared with 98%. Patient-reported antibiotic use within seven days post-inclusion was also significantly lower in intervention sites. Conclusions: The results showed a reduction in potential antibiotic overuse and hospital admissions (i.e., hospitalization rates within seven days) in both the Burkina Faso and Ivory Coast interventions sites. These findings emphasize the importance of enhanced diagnostic strategies for the improvement of patient outcomes and the fight against antibiotic resistance. This study also highlights the need for implementing systematic and differential diagnosis of dengue and chikungunya in West Africa where febrile infections are endemic. Further studies are warranted to explore the economic benefits of these diagnostic strategies.
- 8 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2269
Open AccessImproving Management of Viral Febrile Illness and Reducing the Need for Empiric Antibiotics Using VIDAS® Immunoassay for Dengue and Chikungunya: A West African Multicentric Study
Background: Dengue and chikungunya are endemic in West Africa, posing significant public health issues. The aim of this study was to evaluate the impact of differential and systematic diagnosis of dengue and chikungunya on patient management and on antibiotic use in Burkina Faso and Ivory Coast. Methods: A multicenter prospective cohort study was conducted in both countries involving patients with suspected dengue and/or chikungunya viremia. VIDAS® diagnostic tests (bioMérieux SA, Marcy-l’Étoile, France) were provided to the intervention sites, while the control sites initially followed standard of care before testing at the end of the study. The primary outcome was defined as antibiotic prescription or non-initiation/discontinuation, and the secondary endpoints included hospital resource use, patient satisfaction, and health-related quality of life (HRQoL), analyzed through Chi-square and logistic regression using SAS software v9.4. Results: Out of 775 enrolled patients, 767 had corresponding VIDAS® Dengue and VIDAS® Chikungunya results, with 570 having recorded antibiotic therapy (initiated, non-initiated or discontinued). Both Burkina Faso and Ivory Coast observed an increase in antibiotic discontinuation (or non-initiation) rates at the intervention sites compared to control sites: increased from 60% to 78% in Burkina Faso and from 36% to 83% in Ivory Coast. Hospitalization rates within seven days following inclusion were also lower in intervention sites than in the control sites: Burkina Faso 41% as compared with 97% and Ivory Coast 24% as compared with 98%. Patient-reported antibiotic use within seven days post-inclusion was also significantly lower in intervention sites. Conclusions: The results showed a reduction in potential antibiotic overuse and hospital admissions (i.e., hospitalization rates within seven days) in both the Burkina Faso and Ivory Coast interventions sites. These findings emphasize the importance of enhanced diagnostic strategies for the improvement of patient outcomes and the fight against antibiotic resistance. This study also highlights the need for implementing systematic and differential diagnosis of dengue and chikungunya in West Africa where febrile infections are endemic. Further studies are warranted to explore the economic benefits of these diagnostic strategies.
- 1 December 2018
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 74 (6) , 452-457
Tuberculose extrapulmonaire versus tuberculose pulmonaire : aspects épidémiologiques, diagnostiques et évolutifs
- 1 December 2018
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 74 (6) , 452-457
Tuberculose extrapulmonaire versus tuberculose pulmonaire : aspects épidémiologiques, diagnostiques et évolutifs
- 1 September 2017
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 34 (7) , 749-757
Test Xpert ® MTB/RIF et dépistage des nouveaux cas de tuberculose pulmonaire en routine dans une zone de haute endémicité tuberculeuse
- 1 September 2017
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 34 (7) , 749-757
Test Xpert ® MTB/RIF et dépistage des nouveaux cas de tuberculose pulmonaire en routine dans une zone de haute endémicité tuberculeuse
- 1 April 2016
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 72 (2) , 129-135
Dynamique des indicateurs de la prise en charge ambulatoire de la tuberculose au centre antituberculeux d’Adjamé
- 1 April 2016
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 72 (2) , 129-135
Dynamique des indicateurs de la prise en charge ambulatoire de la tuberculose au centre antituberculeux d’Adjamé
- 1 April 2016
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 72 (2) , 109-114
Profil clinique, paraclinique et évolutif du sujet infecté par le VIH comparé à celui du sujet non infecté par le VIH en milieu pneumologique hospitalier à Abidjan
- 1 April 2016
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 72 (2) , 109-114
Profil clinique, paraclinique et évolutif du sujet infecté par le VIH comparé à celui du sujet non infecté par le VIH en milieu pneumologique hospitalier à Abidjan
- 1 January 2016
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 33 (1) , 47-55
Diagnostic comparé des pneumopathies bactériennes et de la tuberculose pulmonaire chez les patients VIH+
- 1 January 2016
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 33 (1) , 47-55
Diagnostic comparé des pneumopathies bactériennes et de la tuberculose pulmonaire chez les patients VIH+
- 20 December 2015
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 33, A153-A154
Dynamique des indicateurs de la prise en charge ambulatoire de la tuberculose au centre antituberculeux d’Adjamé
- 20 December 2015
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 33, A153-A154
Dynamique des indicateurs de la prise en charge ambulatoire de la tuberculose au centre antituberculeux d’Adjamé
- Open Access
- 1 January 2014
- Published by JLE in L'information psychiatrique
- Vol. 90 (5) , 373-379
Anxiété et dépression au cours du traitement antirétroviral à Abidjan
Introduction HIV infection and antiretroviral therapy (ARV) treatment are associated with anxio-depressive disorders which are linked to the characteristics of the patients. The aim of the study was to identify the risk factors of these disorders within the group of HIV infected patients and under the monitoring of antiretroviral therapy. Methodology our study was prospective and transversal within patients undergoing antiretroviral therapy for at least 2 years. Anxiety and depression were considered certain for scores of anxiety > 10 and for depression > 10 according to the questionnaire “Hospital Anxiety and depression scale”. Results Anxiety was found in 31.5 % of the cases (39/124) and depression in 9.7 % of the cases (12/124). At the ARV initiation, anxiety was found in patients with a rate of lymphocytes T CD4 ≥ 200 / ml in 15.2 % of cases (7/46) against 40.8 % of cases (29/71) within subjects having a rate of lymphocytes T CD4 < 200 / ml [p = 0.003 ; OR = 0.260 (0.102 - 0,661]. In multivariate analysis, independent factors were associated with a reduction of depression : fact of having children [p = 0.024 ; OR = 0.128 (0.022 – 0.760], last rate of lymphocytes T CD4 > 200 [p = 0.031 ; OR = 0.148 (0.026 – 0.836)]. Conclusion during the management of HIV patients infected in the pneumology department of Cocody, anxio-depressive disorders are present in the patients without children, detected at the advanced stage of the disease or in therapeutic failure.
- 1 January 2014
- Published by JLE in L'information psychiatrique
- Vol. 90 (5) , 373-379
Open AccessAnxiété et dépression au cours du traitement antirétroviral à Abidjan
Introduction HIV infection and antiretroviral therapy (ARV) treatment are associated with anxio-depressive disorders which are linked to the characteristics of the patients. The aim of the study was to identify the risk factors of these disorders within the group of HIV infected patients and under the monitoring of antiretroviral therapy. Methodology our study was prospective and transversal within patients undergoing antiretroviral therapy for at least 2 years. Anxiety and depression were considered certain for scores of anxiety > 10 and for depression > 10 according to the questionnaire “Hospital Anxiety and depression scale”. Results Anxiety was found in 31.5 % of the cases (39/124) and depression in 9.7 % of the cases (12/124). At the ARV initiation, anxiety was found in patients with a rate of lymphocytes T CD4 ≥ 200 / ml in 15.2 % of cases (7/46) against 40.8 % of cases (29/71) within subjects having a rate of lymphocytes T CD4 < 200 / ml [p = 0.003 ; OR = 0.260 (0.102 - 0,661]. In multivariate analysis, independent factors were associated with a reduction of depression : fact of having children [p = 0.024 ; OR = 0.128 (0.022 – 0.760], last rate of lymphocytes T CD4 > 200 [p = 0.031 ; OR = 0.148 (0.026 – 0.836)]. Conclusion during the management of HIV patients infected in the pneumology department of Cocody, anxio-depressive disorders are present in the patients without children, detected at the advanced stage of the disease or in therapeutic failure.
- 1 June 2012
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 68 (3) , 180-184
Dynamique de la pathologie respiratoire dans un service de pneumologie en Afrique noire dans le contexte de l’infection à VIH de 1998 à 2007
- 1 June 2012
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 68 (3) , 180-184
Dynamique de la pathologie respiratoire dans un service de pneumologie en Afrique noire dans le contexte de l’infection à VIH de 1998 à 2007
- 30 September 2011
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 28 (7) , 894-902
Facteurs prédictifs du statut « perdus de vue » au cours du traitement de la tuberculose
- 30 September 2011
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 28 (7) , 894-902
Facteurs prédictifs du statut « perdus de vue » au cours du traitement de la tuberculose